Multi-Cancer Blood Test Moves Closer to FDA Approval

Multi-Cancer Blood Test Gets FDA Panel Backing

The multi-cancer blood test has taken a step toward approval in the United States. The US FDA advisory panel has endorsed Grails Galleri test, which looks for signs of than 50 types of cancer using a single blood draw. The panels vote is advice, not a decision so the FDA still has to rule on the test.

How the multi-cancer blood test works

The Galleri test does not diagnose cancer. It searches the blood for DNA fragments shed by tumour cells and flags a signal that may point to cancer. Grail says it can pick up signs of cancers that have no routine screening today including liver and ovarian cancer. Doctors would then need tests to confirm whether cancer is present.

Why the panel urged caution

Even though the panel endorsed the test its members stressed that it is far from clear how well the technology performs. The main concerns were:

• Grail has not shown that screening with the test lowers cancer deaths, which would take years of follow‑up.
• A negative result does not guarantee that a person is cancer‑free.
• Consumer advocates warned that patients might ignore symptoms after an all‑clear result.

A Johns Hopkins scientist described the test as promising. Said doctors and patients must understand its pros and cons.

What approval could change

At present the multi‑cancer blood test is sold in the US without FDA approval. Patients pay about $949 out of pocket. Approval could open the door to coverage by Medicare and private insurers which would make the multi‑cancer blood test available to more people. Whether insurers will actually cover it is a question and it depends on the evidence they see.

What happens next

The FDA is expected to make its ruling after considering the panels advice. Until then the multi‑cancer blood test remains an option and standard screenings such as mammograms and colonoscopies continue to be the proven methods. Researchers say more study is needed to prove whether the multi‑cancer blood test is as beneficial, as those established screenings.

Source: Associated Press, FDA panel endorses first-of-a-kind cancer blood test from Grail

Frequently asked questions

Q.What is a multi-cancer blood test?

• A multi-cancer blood test checks a single blood sample for signs that a person may have one of many types of cancer. Grail’s Galleri test looks for DNA fragments shed by tumour cells and flags a signal that may point to cancer. It does not diagnose cancer on its own.

Q.How many cancers can the Galleri test detect?

• Grail says the test can pick up signs of more than 50 types of cancer. This includes cancers such as liver and ovarian cancer, which have no routine screening option today.

Q.Has the FDA approved the multi-cancer blood test?

• Not yet. An FDA advisory panel has endorsed the test, but the panel’s vote is only advice. The FDA still has to make its final decision.

Q.Can a multi-cancer blood test replace mammograms or colonoscopies?

• No. Researchers say more study is needed to prove whether the test is as beneficial as established screenings. Mammograms and colonoscopies remain the proven methods, and Grail itself describes the test as a complement to them.

Q.Does a negative result mean I do not have cancer?

• No. A negative result does not guarantee that a person is cancer-free. Consumer advocates have warned that people might ignore early symptoms after an all-clear result, so symptoms should always be checked by a doctor.

Q.Has the test been shown to reduce cancer deaths?

• Not yet. Grail has not provided data showing that screening with the test leads to fewer cancer deaths. Proving that would require years of follow-up.

Q.How much does the test cost, and is it covered by insurance?

• In the US, the test costs about $949 and is not covered by Medicare or most private insurance. FDA approval could open the door to coverage, although insurers would still need to be convinced by the evidence.

Q.What happens after the FDA panel vote?

• The FDA will consider the panel’s advice and then make its final ruling. Until then, the test remains an unapproved option sold in the US, and standard screenings remain the proven choice.